168 related articles for article (PubMed ID: 37207683)
1. Human papillomavirus vaccine effect against human papillomavirus infection in Rwanda: evidence from repeated cross-sectional cervical-cell-based surveys.
Sayinzoga F; Tenet V; Heideman DAM; Sibomana H; Umulisa MC; Franceschi S; Hakizimana JD; Clifford GM; Baussano I
Lancet Glob Health; 2023 Jul; 11(7):e1096-e1104. PubMed ID: 37207683
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of Human Papillomavirus and Estimation of Human Papillomavirus Vaccine Effectiveness in Thimphu, Bhutan, in 2011-2012 and 2018 : A Cross-sectional Study.
Baussano I; Tshomo U; Tenet V; Heideman DAM; Wangden T; Franceschi S; Clifford GM
Ann Intern Med; 2020 Dec; 173(11):888-894. PubMed ID: 32956600
[TBL] [Abstract][Full Text] [Related]
3. Human papillomavirus infection in Rwanda at the moment of implementation of a national HPV vaccination programme.
Ngabo F; Franceschi S; Baussano I; Umulisa MC; Snijders PJ; Uyterlinde AM; Lazzarato F; Tenet V; Gatera M; Binagwaho A; Clifford GM
BMC Infect Dis; 2016 May; 16():225. PubMed ID: 27221238
[TBL] [Abstract][Full Text] [Related]
4. Impact of Human Papillomavirus Vaccination, Rwanda and Bhutan.
Baussano I; Sayinzoga F; Tshomo U; Tenet V; Vorsters A; Heideman DAM; Gheit T; Tommasino M; Umulisa MC; Franceschi S; Clifford GM
Emerg Infect Dis; 2021 Jan; 27(1):1-9. PubMed ID: 33350922
[TBL] [Abstract][Full Text] [Related]
5. Urine testing to monitor the impact of HPV vaccination in Bhutan and Rwanda.
Franceschi S; Chantal Umulisa M; Tshomo U; Gheit T; Baussano I; Tenet V; Tshokey T; Gatera M; Ngabo F; Van Damme P; Snijders PJ; Tommasino M; Vorsters A; Clifford GM
Int J Cancer; 2016 Aug; 139(3):518-26. PubMed ID: 26991686
[TBL] [Abstract][Full Text] [Related]
6. Human papillomavirus vaccine coverage in Rwanda: A population-level analysis by birth cohort.
Sayinzoga F; Umulisa MC; Sibomana H; Tenet V; Baussano I; Clifford GM
Vaccine; 2020 May; 38(24):4001-4005. PubMed ID: 32336599
[TBL] [Abstract][Full Text] [Related]
7. Impact of one and two human papillomavirus (HPV) vaccine doses on community-level HPV prevalence in South African adolescent girls: study protocol and rationale for a pragmatic before-after design.
Machalek D; Rees H; Chikandiwa A; Munthali R; Travill D; Mbulawa Z; Petoumenos K; Delany-Moretlwe S; Kaldor J;
BMJ Open; 2022 Feb; 12(2):e059968. PubMed ID: 35144959
[TBL] [Abstract][Full Text] [Related]
8. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study.
Tabrizi SN; Brotherton JM; Kaldor JM; Skinner SR; Liu B; Bateson D; McNamee K; Garefalakis M; Phillips S; Cummins E; Malloy M; Garland SM
Lancet Infect Dis; 2014 Oct; 14(10):958-66. PubMed ID: 25107680
[TBL] [Abstract][Full Text] [Related]
9. Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study.
Kavanagh K; Pollock KG; Cuschieri K; Palmer T; Cameron RL; Watt C; Bhatia R; Moore C; Cubie H; Cruickshank M; Robertson C
Lancet Infect Dis; 2017 Dec; 17(12):1293-1302. PubMed ID: 28965955
[TBL] [Abstract][Full Text] [Related]
10. Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis.
Drolet M; Laprise JF; Martin D; Jit M; Bénard É; Gingras G; Boily MC; Alary M; Baussano I; Hutubessy R; Brisson M
Lancet Infect Dis; 2021 Nov; 21(11):1598-1610. PubMed ID: 34245682
[TBL] [Abstract][Full Text] [Related]
11. Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study.
Gertig DM; Brotherton JM; Budd AC; Drennan K; Chappell G; Saville AM
BMC Med; 2013 Oct; 11():227. PubMed ID: 24148310
[TBL] [Abstract][Full Text] [Related]
12. Evidence-based impact projections of single-dose human papillomavirus vaccination in India: a modelling study.
Man I; Georges D; de Carvalho TM; Ray Saraswati L; Bhandari P; Kataria I; Siddiqui M; Muwonge R; Lucas E; Berkhof J; Sankaranarayanan R; Bogaards JA; Basu P; Baussano I
Lancet Oncol; 2022 Nov; 23(11):1419-1429. PubMed ID: 36174583
[TBL] [Abstract][Full Text] [Related]
13. The impact of over ten years of HPV vaccination in England: Surveillance of type-specific HPV in young sexually active females.
Checchi M; Mesher D; Panwar K; Anderson A; Beddows S; Soldan K
Vaccine; 2023 Oct; 41(45):6734-6744. PubMed ID: 37821315
[TBL] [Abstract][Full Text] [Related]
14. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.
Armstrong EP
J Manag Care Pharm; 2010 Apr; 16(3):217-30. PubMed ID: 20331326
[TBL] [Abstract][Full Text] [Related]
15. Potential population-level effectiveness of one-dose HPV vaccination in low-income and middle-income countries: a mathematical modelling analysis.
Bénard É; Drolet M; Laprise JF; Gingras G; Jit M; Boily MC; Bloem P; Brisson M
Lancet Public Health; 2023 Oct; 8(10):e788-e799. PubMed ID: 37777288
[TBL] [Abstract][Full Text] [Related]
16. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
17. Long-term human papillomavirus vaccination effectiveness and immunity in Rwandan women living with and without HIV: a study protocol.
Murenzi G; Shumbusho F; Hansen N; Munyaneza A; Gage JC; Muhoza B; Kanyabwisha F; Pierz A; Tuyisenge P; Anastos K; Castle PE
BMJ Open; 2022 Aug; 12(8):e061650. PubMed ID: 36008069
[TBL] [Abstract][Full Text] [Related]
18. Changes in genital Human Papillomavirus (HPV) prevalence among urban females a decade after the Malaysian HPV vaccination program.
Khoo SP; Muhammad Ridzuan Tan NA; Rajasuriar R; Nasir NH; Gravitt P; Ng CW; Woo YL
PLoS One; 2022; 17(12):e0278477. PubMed ID: 36538522
[TBL] [Abstract][Full Text] [Related]
19. Reduction in Vaccine HPV Type Infections in a Young Women Group (18-25 Years) Five Years after HPV Vaccine Introduction in Colombia.
Combita AL; Reyes V; Puerto D; Murillo R; Sánchez R; Nuñez M; Hernandez-Suarez GA; Wiesner C
Cancer Prev Res (Phila); 2022 Jan; 15(1):55-66. PubMed ID: 34610993
[TBL] [Abstract][Full Text] [Related]
20. Modelling the population-level impact of vaccination on the transmission of human papillomavirus type 16 in Australia.
Regan DG; Philp DJ; Hocking JS; Law MG
Sex Health; 2007 Sep; 4(3):147-63. PubMed ID: 17931528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
